Contents

Search

NuvaRing (etonogestrel, ethinyl estradiol)

A vaginal contraceptive ring. FDA approved 2001 Dosage: - leave ring in for 3 weeks; remove for 4th week of cycle - if ring is expelled, may be washed & resinserted - use back-up contraception if ring has been removed > 3 hours - continue backup contraception until ring has been in place 7 days Adverse effects: - 2-fold increased risk relative to oral contraceptives [4] Mechanism of action: 1) small vaginal ring 2) releases etonogestrel + ethinyl estradiol Notes: - lowest estrogen exposure vs patch, oral contraceptive [3]

Interactions

drug adverse effects of estrogens

General

hormonal contraceptive vaginal ring ethinyl estradiol/etonogestrel

Database Correlations

PUBCHEM cid=208920

References

  1. Prescriber's Letter 9(2):S1 2002
  2. Prescriber's Letter 9(6):32 2002
  3. van den Heuvel MW, van Bragt AJ, Alnabawy AK, Kaptein MC. Comparison of ethinylestradiol pharmacokinetics in three hormonal contraceptive formulations: the vaginal ring, the transdermal patch and an oral contraceptive. Contraception. 2005 Sep;72(3):168-74. PMID: 16102549
  4. Lidegaard O et al Venous thrombosis in users of non-oral hormonal contraception: follow-up study, Denmark 2001-10 BMJ 2012;344:e2990 PMID: 22577198 http://www.bmj.com/content/344/bmj.e2990
  5. Lidegaard O et al Thrombotic Stroke and Myocardial Infarction with Hormonal Contraception N Engl J Med 2012; 366:2257-2266June 14, 2012 PMID: 22693997 http://www.nejm.org/doi/full/10.1056/NEJMoa1111840 - Petitti DB Hormonal Contraceptives and Arterial Thrombosis - Not Risk-free but Safe Enough N Engl J Med 2012; 366:2316-2318June 14, 2012 PMID: 22694003 http://www.nejm.org/doi/full/10.1056/NEJMe1204769
  6. Organon. http://www.nuvaring.com

Components

ethinyl estradiol etonogestrel (3-oxodesogestrel)